Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem?

Omer O, Cohen P, Neong SF, Smith GV.

Frontline Gastroenterol. 2016 Jul;7(3):222-226. doi: 10.1136/flgastro-2014-100458. Epub 2014 Sep 22.

2.

Dysplasia and colorectal cancer surveillance in inflammatory bowel disease.

Pulusu SSR, Lawrance IC.

Expert Rev Gastroenterol Hepatol. 2017 Aug;11(8):711-722. doi: 10.1080/17474124.2017.1327347. Epub 2017 May 16. Review.

PMID:
28475382
3.
4.

CANCERPREVENTIVE IN ULCERATIVE COLITIS.

Podolskaya DV, Shapina MV, Khalif IL.

Eksp Klin Gastroenterol. 2016;(8):4-8. Review. English, Russian.

PMID:
29874428
5.

Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.

Do EJ, Hwang SW, Kim SY, Ryu YM, Cho EA, Chung EJ, Park S, Lee HJ, Byeon JS, Ye BD, Yang DH, Park SH, Yang SK, Kim JH, Myung SJ.

J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. doi: 10.1111/jgh.13280.

PMID:
26711554
6.

Chemoprevention of colorectal neoplasia.

Wakeman C, Keenan J, Eteuati J, Hollington P, Eglinton T, Frizelle F.

ANZ J Surg. 2017 Dec;87(12):E228-E232. doi: 10.1111/ans.13392. Epub 2015 Dec 21.

PMID:
26686322
7.

PAK1 promotes intestinal tumor initiation.

Dammann K, Khare V, Harpain F, Lang M, Kurtovic A, Mesteri I, Evstatiev R, Gasche C.

Cancer Prev Res (Phila). 2015 Nov;8(11):1093-101. doi: 10.1158/1940-6207.CAPR-15-0205-T. Epub 2015 Aug 24.

8.

PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation.

Dammann K, Khare V, Lang M, Claudel T, Harpain F, Granofszky N, Evstatiev R, Williams JM, Pritchard DM, Watson A, Gasche C.

Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2349-60. doi: 10.1016/j.bbamcr.2015.05.031. Epub 2015 May 31.

9.

Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer.

Khare V, Dammann K, Asboth M, Krnjic A, Jambrich M, Gasche C.

Inflamm Bowel Dis. 2015 Feb;21(2):287-96. doi: 10.1097/MIB.0000000000000281.

10.

Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.

Kortüm B, Campregher C, Lang M, Khare V, Pinter M, Evstatiev R, Schmid G, Mittlböck M, Scharl T, Kucherlapati MH, Edelmann W, Gasche C.

Gut. 2015 Dec;64(12):1905-12. doi: 10.1136/gutjnl-2014-307663. Epub 2014 Nov 26.

11.

[Chemoprevention of colorectal cancer in inflammatory bowel disease].

Han SH, Lee J.

Korean J Gastroenterol. 2014 Jan 25;63(1):3-10. Review. Korean.

12.

Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question.

Margagnoni G, Pagnini C, Menasci F, Festa S, Delle Fave G.

Curr Clin Pharmacol. 2014 Feb;9(1):84-90. Review.

PMID:
24218994
13.

Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells.

Khare V, Lang M, Dammann K, Campregher C, Lyakhovich A, Gasche C.

Biochem Pharmacol. 2014 Jan 15;87(2):312-20. doi: 10.1016/j.bcp.2013.10.021. Epub 2013 Oct 30.

14.

5-Aminosalicylic acid and chemoprevention: does it work?

Lopez A, Peyrin-Biroulet L.

Dig Dis. 2013;31(2):248-53. doi: 10.1159/000353806. Epub 2013 Sep 6. Review.

PMID:
24030235
15.

Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer.

Stolfi C, De Simone V, Pallone F, Monteleone G.

Int J Mol Sci. 2013 Sep 3;14(9):17972-85. doi: 10.3390/ijms140917972. Review.

16.

Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study.

Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR.

Clin Gastroenterol Hepatol. 2013 Dec;11(12):1601-8.e1-4. doi: 10.1016/j.cgh.2013.06.023. Epub 2013 Jul 17.

17.

Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments.

Chan MV, Wallace JL.

Am J Physiol Gastrointest Liver Physiol. 2013 Oct 1;305(7):G467-73. doi: 10.1152/ajpgi.00169.2013. Epub 2013 Jul 18. Review.

18.

Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.

Managlia E, Katzman RB, Brown JB, Barrett TA.

Inflamm Bowel Dis. 2013 Sep;19(10):2051-60. doi: 10.1097/MIB.0b013e318297d741.

PMID:
23867870
19.

Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).

Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, Marti-Gallostra M, Spinelli A, van der Meulen-de Jong AE, Yuksel ES, Gasche C, Ardizzone S, Danese S.

J Crohns Colitis. 2014 Jan;8(1):5-18. doi: 10.1016/j.crohns.2013.04.008. Epub 2013 May 9. Review.

PMID:
23664897
20.

The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.

Herfarth H.

Dig Dis. 2012;30 Suppl 2:55-9. doi: 10.1159/000341894. Epub 2012 Nov 23. Review.

PMID:
23207933

Supplemental Content

Loading ...
Support Center